|Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome|
M Tartaglia, LA Pennacchio, C Zhao, KK Yadav, V Fodale, A Sarkozy, ...
Nature genetics 39 (1), 75-79, 2007
|An orthosteric inhibitor of the Ras-Sos interaction|
A Patgiri, KK Yadav, PS Arora, D Bar-Sagi
Nature chemical biology 7 (9), 585-587, 2011
|Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death|
H Hieronymus, R Murali, A Tin, K Yadav, W Abida, H Moller, D Berney, ...
Elife 7, e37294, 2018
|exRNA atlas analysis reveals distinct extracellular RNA cargo types and their carriers present across human biofluids|
OD Murillo, W Thistlethwaite, J Rozowsky, SL Subramanian, R Lucero, ...
Cell 177 (2), 463-477. e15, 2019
|Integrated nanoscale deterministic lateral displacement arrays for separation of extracellular vesicles from clinically-relevant volumes of biological samples|
JT Smith, BH Wunsch, N Dogra, ME Ahsen, K Lee, KK Yadav, R Weil, ...
Lab on a Chip 18 (24), 3913-3925, 2018
|The use of biomarkers in prostate cancer screening and treatment|
AV Alford, JM Brito, KK Yadav, SS Yadav, AK Tewari, J Renzulli
Reviews in urology 19 (4), 221, 2017
|Intratumor heterogeneity in prostate cancer|
SS Yadav, JA Stockert, V Hackert, KK Yadav, AK Tewari
Urologic Oncology: Seminars and Original Investigations 36 (8), 349-360, 2018
|Radiomics features measured with multiparametric magnetic resonance imaging predict prostate cancer aggressiveness|
SJ Hectors, M Cherny, KK Yadav, AT Beksaç, H Thulasidass, S Lewis, ...
The Journal of urology 202 (3), 498-505, 2019
|Allosteric gating of Son of sevenless activity by the histone domain|
KK Yadav, D Bar-Sagi
Proceedings of the National Academy of Sciences 107 (8), 3436-3440, 2010
|Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment|
SS Yadav, J Li, HJ Lavery, KK Yadav, AK Tewari
Urologic Oncology: Seminars and Original Investigations 33 (6), 267. e1-267. e13, 2015
|One-way membrane trafficking of SOS in receptor-triggered Ras activation|
SM Christensen, HL Tu, JE Jun, S Alvarez, MG Triplet, JS Iwig, KK Yadav, ...
Nature structural & molecular biology 23 (9), 838-846, 2016
|Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences|
W Rayford, AT Beksac, J Alger, M Alshalalfa, M Ahmed, I Khan, ...
Communications biology 4 (1), 670, 2021
|Inflammation and prostate cancer|
AK Tewari, JA Stockert, SS Yadav, KK Yadav, I Khan
Cell & Molecular Biology of Prostate Cancer: Updates, Insights and New …, 2018
|Predictive value of pseudouridine in prostate cancer|
JA Stockert, A Gupta, B Herzog, SS Yadav, AK Tewari, KK Yadav
American journal of clinical and experimental urology 7 (4), 262, 2019
|Induction of neuroendocrine differentiation in prostate cancer cells by dovitinib (TKI-258) and its therapeutic implications|
SS Yadav, J Li, JA Stockert, B Herzog, J O'Connor, L Garzon-Manco, ...
Translational oncology 10 (3), 357-366, 2017
|Combination effect of therapies targeting the PI3K-and AR-signaling pathways in prostate cancer|
SS Yadav, J Li, JA Stockert, J O'Connor, B Herzog, C Elaiho, MD Galsky, ...
Oncotarget 7 (46), 76181, 2016
|Multiparametric magnetic resonance imaging features identify aggressive prostate cancer at the phenotypic and transcriptomic level|
AT Beksac, S Cumarasamy, U Falagario, P Xu, M Takhar, M Alshalalfa, ...
The Journal of Urology 200 (6), 1241-1249, 2018
|Pseudouridine as a novel biomarker in prostate cancer|
JA Stockert, R Weil, KK Yadav, N Kyprianou, AK Tewari
Urologic Oncology: Seminars and Original Investigations 39 (1), 63-71, 2021
|Systems medicine approaches to improving understanding, treatment, and clinical management of neuroendocrine prostate cancer|
K K Yadav, K Shameer, B Readhead, S S Yadav, L Li, A Kasarskis, ...
Current Pharmaceutical Design 22 (34), 5234-5248, 2016
|Analysis of real-world data to investigate the impact of race and ethnicity on response to programmed cell death-1 and programmed cell death-ligand 1 inhibitors in advanced non …|
KL Ayers, T Mullaney, X Zhou, JJ Liu, K Lee, M Ma, S Jones, L Li, ...
The Oncologist 26 (7), e1226-e1239, 2021